RuiXin Medical Showcases Integrated AI-Powered Cardiovascular Diagnostic and Interventional Platform at Shenzhen International High-Performance Medical Devices & Innovative Pharma Expo

Recently, RaysightMed appeared at the Shenzhen International High-Performance Medical Device Exhibition and Innovative Pharmaceutical Exhibition. As a representative of a cutting-edge technology enterprise, it was invited to attend the "Policy Guidance · Financial Empowerment" — Shenzhen Medical Insurance Policy Promotion and Innovative Medical Device Achievement Transformation Financing Matchmaking Conference, where it delivered a keynote speech, sharing advanced technologies and industry practices in the field of cardiovascular intelligent diagnosis and treatment.

This exhibition was jointly hosted by the Chinese Medical Equipment Association, the National High-Performance Medical Device Innovation Center, and the Shenzhen Medical Device Industry Association.The exhibition, themed "Innovative Pharmaceuticals and Medical Devices: Integration for Win-Win Outcomes,"More than 300 global leading medical device and pharmaceutical companies showcased over a thousand innovative products.

BuildIntegrated Platform for Precision Cardiovascular Interventional Diagnosis and Treatment

During the presentation, RaysightMed showcased an integrated cardiovascular precision interventional diagnosis and treatment platform that covers the entire process from "preoperative screening - intraoperative intelligent diagnosis and treatment - postoperative health management."

Specifically, during the preoperative screening and postoperative health management processes, RuiXin-FFR by RaysightMed utilizes AI and 3D fluid dynamics technology to assess coronary functional blood flow reserve fraction (FFR) values based on non-invasive CT imaging, while also quantifying parameters such as plaque stress through 3D color-coded maps.Accurate screening of myocardial ischemia and support for preoperative planning of virtual stenting, simulation of stent implantation effects, and assistance in formulating PCI or bypass plans.。

InIntraoperative Intelligent Diagnosis and Treatment, RaysightMedAngioQFA, based on coronary angiography images, synchronously outputs FFR, microcirculatory resistance index IMR within 10 seconds.Vessel Stenosis Rate QCA,Real-time Guidance for Stent Size and Position Selection through "Morphology + Function" Dual Assessment，Diagnostic Accuracy Exceeds 95%。

RaysightMed Intracardiac Echocardiography Diagnostic System and Single-Use Intracardiac Echocardiography Catheter,Using AI to combine multi-modal images of cardiac CT and DSA,Preoperative Planning and Intraoperative Navigation for Electrophysiology and Structural Heart Surgeries。

Fully automatic AI vascular interventional robot is driven by the doctor's voice commands to execute AI-powered surgery, adopting a master-slave separation design.Now, sub-millimeter level control of guidewires/catheters, combined with force feedback and 5G remote capabilities,Complete operations such as balloon dilation and stent implantation while reducing radiation risks.。

Achieve Systemic Innovation, Benefit Clinics, Patients and Industry

At the exhibition area, RaysightMed showcased the AngioQFA system on-site, providing attendees with an intuitive demonstration of the product's features and advantages, which garnered positive attention and inquiries from the audience.

The full-process closed-loop of cardiovascular intelligent diagnosis and treatment constructed by RaysightMed is not only a technical integration, but alsoSystematic Innovation Driven by the Synergistic Advancement of Clinical Practice, Industrial Development, and Patient Benefits。

For Clinical: Towards a New Stage of Precision and Standardized Diagnosis and Treatment

Full-process solutions assist in non-invasive and precise preoperative assessment, reduce unnecessary invasive examinations, enable real-time functional and morphological synchronous analysis during surgery, support more accurate and scientific treatment decisions, and AI surgical robots enhance operational precision while reducing radiation exposure.Promote the Intelligent and Standardized High-Quality Pathway for Cardiovascular Diagnosis and Treatment。

For the industry: Promoting domestic innovation and ecological collaboration

This solution not only supports the domestic production substitution of high-end medical devices but also accelerates the transformation of new technologies from the laboratory to clinical application through close collaboration in "industry, academia, research, and use."Provide a model for the autonomous control and iterative upgrading of China's high-performance medical device industry chain.。

For patients: Enhancing the safety and accessibility of diagnosis and treatment

Full-process intelligence means more accurate diagnosis, more personalized treatment, and ultimately benefits the patients.Lower risks, faster recovery, and more reasonable medical expensesEspecially with the integration of 5G-enabled remote surgery capabilities, intelligent diagnosis and treatment technologies are expected to benefit more grassroots patients.

Through this exhibition, RaysightMed engaged in in-depth exchanges with policymakers, clinicians, investors, and industry players. Moving forward, the company will continue to promote the implementation and application of intelligent diagnostic and treatment technologies, working hand-in-hand with ecosystem partners.Jointly promote the high-quality development of China's high-performance medical device industry, provide more precise diagnosis and treatment solutions for clinical use, and offer patients more accurate and safer diagnosis and treatment services.Service。

RaysightMed CEO Zheng Lingxiao Interprets the New Paradigm of "Macro + Micro" AI Coronary Diagnosis and Treatment at Jinan University

University-Enterprise Collaboration | RaysightMed Partners with the First Affiliated Hospital of Jinan University to Jointly Cultivate Interdisciplinary Talents in Intelligent Healthcare

Comprehensive and Precise, Evidence-Based Decision-Making | Zhangzhou People's Hospital Utilizes RaysightMed AngioQFA to Successfully Diagnose and Treat Occult Coronary Artery Disease